Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

Adaptive Biotechnologies Corporation announced a partnership with Epic to integrate the clonoSEQ® Assay into Epic’s comprehensive electronic medical record system. For patients with blood cancers, clonoSEQ is the only FDA-cleared test that can monitor minimal residual disease.